Thomson Scientific Launches Thomson Innovation

The Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has launched its new intellectual property research and analysis solution, Thomson Innovation. For the first time, researchers will be able to simultaneously search worldwide editorially enhanced patent data, Asian patent data translated into English, scientific literature, and business and news sources.

"The global intellectual property market is changing rapidly, and organizations need to be aware of changes in the evolving landscape, such as the proliferation of patenting activity in Asia," said David Brown, Executive Vice President, Corporate Markets, Thomson Scientific. "It's more critical than ever for our customers to have access to the most authoritative patent data, and to incorporate complementary sources, like scientific literature, in their intellectual property research."

Designed in collaboration with more than 1,800 customers, Thomson Innovation sets a new standard in intellectual property research and analysis that will help companies accelerate ideation, improve productivity, minimize risks and gain a competitive advantage. It provides:

  • Comprehensive prior art searching with the ability to search patents and scientific literature simultaneously
  • Expanded Asian patent coverage, including translations of Japanese full-text and additional editorially enhanced abstracts of Chinese data
  • A fully integrated searchable database combining Derwent World Patent Index® (DWPISM) with full-text patent data to provide the most comprehensive patent records available
  • Support of strategic intellectual property decisions through:
    • powerful analysis and visualization tools, such as charting, citation mapping and search result ranking
    • and, integration of business and news resources
  • Enhanced collaboration capabilities, including customizable folder structures that enable users to organize, annotate, search and share relevant files

Thomson Innovation is being launched in phases, and the first release is available now and includes global, full-text patent sources, including Japan. In rapid succession, it will be followed by the addition of Derwent World Patents Index, scientific literature, business information and news. A series of additional enhancements will be delivered throughout 2008.

For more information about Thomson Innovation, visit www.thomsoninnovation.com.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation’s common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC). Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development—from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...